. 2013 Mar 27;43(5):483–491. doi: 10.1093/jjco/hyt040

Table 2.

Risk factors for grade 3–4 leukopenia, thrombocytopenia and diarrhea in patients receiving irinotecan therapy

Variable	G3–4 leukopenia					G3–4 thrombocytopenia					G3–4 diarrhea
	n^a	Univariate		Multivariate (n = 12 023)		n^a	Univariate		Multivariate (n = 12 022)		n^a	Univariate		Multivariate (n = 11 983)
	n^a	Odds (95% CI)	P value^c	Odds (95% CI)	P value^c	n^a	Odds (95% CI)	P value^c	Odds (95% CI)	P value^c	n^a	Odds (95% CI)	P value^c	Odds (95% CI)	P value^c
Gender (female/male)	13 915	1.48 (1.38–1.58)	0.0001	1.62 (1.50–1.75)	0.0001	13 915	1.08 (0.98–1.20)	0.1307	1.16 (1.03–1.29)	0.0120	13 861	1.05 (0.94–1.17)	0.4237	1.15 (1.02–1.30)	0.0271
Age (≥65/≤64 years)	13 912	1.20 (1.12–1.30)	0.0001	1.41 (1.30–1.53)	0.0001	13 912	1.37 (1.24–1.52)	0.0001	1.50 (1.34–1.68)	0.0001	13 858	1.34 (1.20–1.50)	0.0001	1.39 (1.22–1.57)	0.0001
PS (≥3/≤2)	13 670	2.05 (1.71–2.45)	0.0001	1.66 (1.36–2.03)	0.0001	13 669	2.79 (2.28–3.42)	0.0001	2.32 (1.85–2.91)	0.0001	13 624	2.01 (1.58–2.54)	0.0001	1.70 (1.31–2.21)	0.0001
Prior chemotherapy	13 804	1.23 (1.14–1.33)	0.0001			13 803	1.56 (1.40–1.75)	0.0001	1.43 (1.26–1.62)	0.0001	13 749	1.01 (0.90–1.14)	0.8347
Prior radiotherapy	13 752	1.63 (1.50–1.77)	0.0001	1.73 (1.58–1.90)	0.0001	13 751	1.37 (1.22–1.54)	0.0001	1.22 (1.07–1.39)	0.0023	13 697	1.21 (1.07–1.38)	0.0035	1.20 (1.05–1.38)	0.0098
Pleural effusion^b	13 328	1.31 (1.15–1.48)	0.0001	1.25 (1.09–1.43)	0.0013	13 327	1.34 (1.13–1.59)	0.0009	1.26 (1.05–1.52)	0.0121	13 283	1.82 (1.53–2.16)	0.0001	1.66 (1.38–2.00)	0.0001
Massive ascites^b	13 324	1.56 (1.33–1.83)	0.0001	1.41 (1.19–1.68)	0.0001	13 323	1.24 (0.99–1.56)	0.0559			13 279	1.39 (1.10–1.76)	0.0061
Watery stool^b	13 453	1.52 (1.01–2.27)	0.0426			13 453	0.73 (0.37–1.45)	0.3617			13 407	4.03 (2.59–6.26)	0.0001	4.14 (2.50–6.85)	0.0001
Infection^b	13 370	1.83 (1.38–2.43)	0.0001	1.70 (1.24–2.31)	0.0009	13 370	2.28 (1.64–3.18)	0.0001	1.87 (1.30–2.68)	0.0007	13 326	2.64 (1.88–3.72)	0.0001	1.99 (1.37–2.90)	0.0003
Jaundice^b	12 771	2.01 (1.27–3.16)	0.0027			12 771	2.96 (1.80–4.88)	0.0001			12 725	0.89 (0.41–1.93)	0.7585
Ileus^b	13 662	2.20 (1.17–4.13)	0.0145			13.662	2.46 (1.20–5.05)	0.0145			13 615	1.02 (0.36–2.86)	0.9764
Hepatic dysfunction^b	13 754	1.45 (1.23–1.71)	0.0001	1.41 (1.18–1.69)	0.0002	13 752	1.51 (1.21–1.88)	0.0002	1.35 (1.07–1.71)	0.0125	13 699	1.30 (1.02–1.67)	0.0366
Renal dysfunction^b	13 754	2.03 (1.65–2.51)	0.0001	1.76 (1.39–2.22)	0.0001	13 752	2.24 (1.75–2.88)	0.0001	1.82 (1.38–2.40)	0.0001	13 699	1.81 (1.36–2.41)	0.0001	1.62 (1.19–2.21)	0.0022
Diabetes^b	13 754	0.75 (0.64–0.86)	0.0001	0.73 (0.62–0.86)	0.0001	13 752	0.98 (0.80–1.20)	0.8385			13 699	1.16 (0.93–1.43)	0.1843

^aNo. of patients for univariate analysis.

^bAt the beginning of irinotecan treatment.

^cWald chi-square test.